News

Drug Combination Impacts Outcomes in Ovarian Cancer Patients without BRCA Mutations

Ron Buckanovich, MD, PhD BRCA mutations in ovarian cancer are a double-edged sword.  While BRCA gene mutation carriers have a significantly higher risk of developing ovarian cancer, BRCA gene mutation in tumors is associated with a significant increase in patient survival.  Scientists believe that... 

Epigenetic Targeting of Ovarian Cancer Stem Cells

(July 29, 2014)   OCRF-funded research published earlier this month provides the first proof of principle that epigenomic strategies efficiently target ovarian cancer stem cells, which are key for treatment resistance and the major factor in therapy failures.  OCRF grantees Kenneth Nephew, PhD and... 

Most High Risk Women Aren’t Aware of Ovarian Cancer Risk

(July 28, 2014) Research published last week in Behavioral Medicine suggests that most high-risk women (>75%) do not know their risk for ovarian cancer. Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage...